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Background. Duchenne/Becker muscular dystrophy (D/BMD) is an X-linked recessive muscle disorder affecting 1/3 500 live male births 
worldwide. Up to 70% of all D/BMD cases are caused by exonic deletions or duplications routinely identified in diagnostic laboratories worldwide. 
The remaining patients harbour other sequence alterations for which testing availability is limited owing to the expense of interrogating the large 
DMD gene. Genetic screening for D/BMD in South Africa currently includes multiple ligase-dependent probe amplification (MLPA) for exonic 
deletions and duplications and linkage analysis. No genetic testing for small mutations in the DMD gene is offered, leaving a third of D/BMD 
families without genetic closure. The advent of potential mutation-specific therapies for DMD necessitates comprehensive testing protocols.
Objective. To investigate the effectiveness and affordability of high-resolution melting curve analysis (hrMCA) for detection of small/point 
mutations in the DMD gene, for possible inclusion into the local public health-funded diagnostic service.
Methods. DNA from 24 patients who had previously tested deletion-negative with multiplex polymerase chain reaction (mPCR) was 
analysed by MLPA and hrMCA.
Results. MLPA revealed eight previously undetected exonic rearrangements: five deletions and three duplications. HrMCA of the remaining 
samples revealed three nonsense, four frameshifts, one splice-site, one missense and one single-base substitution in the Dp427promoter/
exon1 of the DMD gene. In addition, 41 polymorphisms and three changes of uncertain significance were detected.
Conclusion. These findings identify hrMCA as an affordable and effective mutation scanning tool for incorporation into the local 
diagnostic setting, allowing for better genetic counselling of more DMD families and selection of potential candidates for future therapies.
S Afr Med J 2014;104(11):779-784. DOI:10.7196/SAMJ.8257
Duchenne muscular dystrophy (DMD) (OMIM 
#310200) is the most common of the inherited 
muscular dystrophies and is caused by lack or 
faulty production of the dystrophin protein, which 
is a vital component of the dystrophin-associated 
protein complex, critical to the maintenance of the structural 
integrity of muscle fibres. DMD is an X-linked recessive disorder, 
occurring at an incidence of 1/3 500 live male births worldwide.[1] 
It generally manifests in boys between the ages of 2 and 5 years and 
is typically marked by delayed motor milestones and symptoms 
such as frequent falling, difficulty in getting up, gait problems, toe-
walking and flat-footedness.[2] In untreated patients, respiratory 
and cardiac complications result in death at a mean age of 19 years. 
The milder, allelic form of DMD, Becker’s muscular dystrophy 
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(BMD), occurs at a lower frequency (1/18 
450 live male births), with a later age of 
onset, a more diverse presentation and a 
longer life expectancy.[3]
D/BMD is a monogenic disease, caused 
by mutations in the dystrophin-encoding 
DMD gene, which encompasses ~2.5 Mb 
of genomic sequence and a ~14 kb RNA 
transcript, comprising 79 exons and eight 
tissue-specific promoters (Fig. 1). Owing 
to its large size, the DMD gene is prone to 
mutations, of which approximately 70% 
are exonic deletions and duplications. 
These tend to cluster within two hotspot 
regions, spanning exons 44 - 53 and 
2 - 20. The remaining 25 - 35% of the 
disease-associated changes are small/point 
alterations, mostly nonsense, frameshift or 
splice-site mutations.[4] These do not appear 
to exhibit any clustering effect, and because 
of the large size of the DMD gene, continue 
to present a significant diagnostic challenge.
The genetic service for D/BMD at 
Groote Schuur Hospital, Cape Town, 
South Africa (SA) and the Division of 
Human Genetics, University of Cape Town 
(UCT), commenced in 1987 and was the 
first of its kind to be offered nationally 
by the state health services in SA.[5] The 
early testing protocol involved tracking the 
inheritance of the putative X chromosome 
using intragenic linkage markers and 
later included the deletion hotspot screen 
with multiplex polymerase chain reaction 
(mPCR), based on the work published by 
Chamberlain et al.[6] In 2000, the Human 
Genetics Laboratory in Johannesburg 
(now also incorporated into the National 
Health Laboratory Service (NHLS)) began 
diagnostic testing for D/BMD, using a 
similar protocol of mPCR and linkage 
analysis.[7] The genetic service for D/
BMD, currently offered by both centres, 
is extended to state and private patients in 
and outside SA.
Introduction of the multiple ligase-
dependent probe amplification (MLPA) in 
2007 by the NHLS in Cape Town and 
Johannesburg significantly improved 
the level of service, as the detection 
range of the assay spans all exons of the 
DMD gene, allowing for identification of 
exonic rearrangements across the gene, 
not just the hotspots. Furthermore, the 
dosage component of the MLPA enables 
identification of duplications in males and 
determination of female carrier status, 
which could not be achieved with the 
mPCR.[8] Determining the female carrier 
status is a significant aspect of any mole-
cular genetic service for D/BMD, not 
only for the purpose of effective genetic 
counselling but also for clinical monitoring 
and management of D/BMD carriers, who 
develop symptoms in approximately 22% 
of all cases. These may involve a cardiac 
pathology (dilated cardiomyopathy) with 
or without muscle weakness, which varies 
from very mild to a DMD-like clinical 
course.[9] Another advantage of the MLPA 
analysis for D/BMD is better delineation of 
the extent of the exonic deletion/duplication 
in an individual.
Genotype-phenotype correlation studies 
in D/BMD have shown that the disease 
severity is influenced not so much by the 
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Fig. 1. Th e DMD gene and its products. A: Linear representation of the DMD gene located at Xp21 
and its products (adapted from Muntoni et al.[11]). Th e black vertical lines represent the 79 exons of the 
dystrophin gene, distributed over about 2.5 million bases. Th e arrows indicate the various promoters: 
the full-length Dp427 brain (B), muscle (M), and Purkinje (P) promoters; Dp260 (retinal, R), Dp140 
(brain3, B3), Dp116 (Schwann cells, S), and Dp71 (general, G) promoters. B: Th e domain composition 
of the various dystrophin proteins is indicated. Th e amino-terminal domain is followed by the spectrin-
like, the cysteine-rich, and the carboxy-terminal domains. (DMD = Duchenne muscular dystrophy.)
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Fig. 2. Exon phasing of relevant sections of the DMD gene and the predicted eﬀ ect of the deletions 
detected in the cohort. Th e phase of each exon is represented by the shape of extremity of the box 
representing the exon. A vertical line represents an exon starting (or ending) at the 1st (or 3rd) nucleotide 
of a codon. An arrow shape represents an exon starting (or ending) at the 2nd or 3rd nucleotide of a 
codon. A: Out-of-frame deletion of exons 5 - 7. B: Out-of-frame deletion of exon 7. C: Out-of-frame 
deletion of exons 22 - 33. (Adapted with permission from www.humgen.nl/lab-aartsma-rus/. DMD = 
Duchenne muscular dystrophy.)
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size of the mutation, as by: (i) the location 
of the mutation in relation to the critical 
functional domains of the dystrophin 
protein; and (ii) the effect of the mutation 
on the DNA translational open reading 
frame (ORF).[10,11] This so-called ‘reading-
frame hypothesis’ argues that mutations 
that disrupt the ORF result in more severe 
phenotypes (DMD) than those where the 
reading frame is retained (BMD). The 
effect of an exonic rearrangement on the 
ORF and possibly the phenotype can be 
predicted, as the intron-exon boundaries 
have been well characterised and show 
that some exons of the DMD gene do 
not contain an integral number of triplet 
codons and if deleted will result in a 
frameshift of the mRNA (Fig. 2). While 
such predictions made on DNA-based 
test results should be approached with 
caution, they are thought to add value, 
especially in early diagnoses of cases 
with no family history, where possible 
anticipation of the disease severity may 
influence the approach to treatment. 
Nevertheless, molecular confirmation of 
the clinical diagnosis of B/DMD remains 
elusive to approximately a third of the 
SA D/BMD patient population, i.e. those 
carrying small/point mutations.
Recent advances in the development 
of mutation-specific therapies for DMD 
support routine availability of testing for 
most D/BMD-causing mutations. While 
next generation sequencing and microarray 
studies present the ultimate technological 
approach and have been successfully 
employed by investigators abroad,[12,13] 
the platforms are prohibitively expensive 
in the local public health context and the 
bioinformatic support structure required for 
routine implementation is largely unavailable 
at present, though much effort is being made 
in that direction. Similarly, while the cost 
of direct BigDye Terminator sequencing 
(Life Technologies, USA) is no longer seen 
as high in the developed countries, it is 
still an expensive option in SA, especially 
considering the amount of sequencing 
required for analysis of the vast DMD gene. 
The work presented here was undertaken 
in response to the call from the clinical 
community in SA for local availability of 
affordable testing for all, or most, B/DMD-
causing mutations.
Objective
The project was conducted as a pilot study 
aimed at investigating the effectiveness and 
affordability of high-resolution melting 
curve analysis (hrMCA) as a presequencing 
scanning tool for detection of small/point 
mutations in the DMD gene, for possible 
inclusion into the local public health-funded 
diagnostic service.
Methods
Patients and controls
The study panel included 24 unrelated boys 
diagnosed with D/BMD on the basis of 
clinical presentation and elevated creatine 
kinase levels. Laboratory confirmation of the 
diagnosis by immunohistochemistry (IHC) 
of muscle biopsy samples was available in 
13 cases. IHC results were not available or 
muscle biopsies were not performed on the 
remaining 11 patients. Of the 24 boys, all 
of whom had previously tested deletion-
negative with the mPCR hotspot screen 
offered routinely before 2007, 19 had been 
referred from the Neuromuscular Clinic at 
Red Cross War Memorial Children’s Hospital 
in Cape Town and five from other centres in 
the country. The cohort ethnicity reflected 
the patient base of the referral centres. Where 
available, archived DNA was retrieved from 
the DNA Registry (REC/REF 234/2010) 
at the Division of Human Genetics, UCT. 
Alternatively, DNA was extracted from blood 
lymphocytes, using standard techniques. 
DNA samples from two healthy male 
volunteers were obtained for inclusion as 
wild-type controls. The study protocol was 
approved by the Human Research Ethics 
Committee, UCT (REC/REF 416/2008), in 
keeping with the tenets of the Declaration of 
Helsinki (2008).
MLPA analysis
Owing to the limitations of the mPCR 
method, all samples were retested for exonic 
rearrangements using the MLPA (PO34 
and P035 probe mixes (MRC-Holland, 
Netherlands). The MLPA products were 
separated by capillary electro phoresis 
on the ABI 3130xl Genetic Analyser 
(Life Technologies, USA) and the data 
files analysed with the GeneMapper 
v4.1 (Applied Biosystems, USA) and the 
Coffalyser.NET software (www.mlpa.com) 
(details available on request). The probable 
effect of the exonic changes on the ORF 
was predicted using the Reading Frame 
Checker (http://www.humgen.nl/scripts/
DMD_frame.php).
Mutation scanning with hrMCA
Principle
HrMCA is based on the natural process 
of DNA denaturation or ‘melting’ upon 
exposure to a gradual increase in tempera-
ture. Double-stranded DNA (dsDNA) 
dissociates into single-stranded DNA 
(ssDNA) in the presence of an intercalating 
dye, which fluoresces only while incorpor-
ated into dsDNA. The melting process can 
be monitored by measuring the gradually 
diminishing amount of fluorescence 
during strand dissociation, and a melting 
curve is derived by plotting fluorescence v. 
temperature (Fig. 3). It has been recognised 
that the precise shape of the melting curve 
is a function of the DNA sequence. The 
observed thermal denaturation profile is 
characteristic of a specific DNA fragment 
and is dependent on its sequence length, 
base and guanine-cytosine (GC) content.[14] 
Successful hrMCA requires specialised 
instru mentation capable of collecting 
data with exquisite real-time and thermo-
optical precision. In this study, DNA of 
patients who tested MLPA-negative for 
exonic rearrangements was subjected to 
hrMCA on the RotorGene™6000 (Corbett 
Research, Australia), which is a real-time 
PCR and hrMCA platform suitable for a 
reliable high-resolution melting (HRM) 
analysis.[15]
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Fig. 3. High-resolution melting curve analysis and sequencing analysis of a family with a nonsense 
mutation in exon 47. A: A diﬀ erence curve. B: A fl uorescence normalised HRM curve. Th e darkest blue 
line represents the melting profi le of the wild type (normal) DNA; the proband is in light blue and his 
mother (a DMD carrier) in medium blue. C: Sanger sequencing trace of exon 47 in the aﬀ ected proband 
(c.6905G>A). (HRM = high-resolution melting; DMD = Duchenne muscular dystrophy.)
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PCR amplification and hrMCA
The entire coding region of the DMD gene 
in each patient was PCR-amplified and 
subjected to hrMCA on the RotorGene™600, 
using 96 sets M13-tailed primer pairs and 
the EvaGreen (Biotum Inc.) intercalating 
dye. The primers were specifically designed 
for hrMCA and subsequent sequencing as 
published by Almomani et al.[16] Amplification 
efficiency in real time and hrMCA profiles 
of the test v. the wild-type DNA samples 
were compared by visual scrutiny and 
RotorGene™6000 Series Analysis Software 
(details available on request).
Sequencing
Fragments exhibiting altered HRM 
prof iles were sequenced with the uni-
versal M13 sequencing primers and the 
BigDye®Terminator v3.1 mix (Life Tech-
nologies, USA), using standard methods. 
The sequences were compared to the Leiden 
coding reference sequence (www.dmd.
nl), based on the GenBank reference file 
NM_004006.1 of the Dp427m dystrophin 
isoform (with one difference: 12505G>A). 
The output files were analysed with the 
BioEdit Sequence Alignment Editor and the 
NCBI Basic Local Alignment Search Tool 
(BLAST) (www.ncbi.nlm.nih.gov).
Bioinformatic analysis
Possible disease association of the sequence 
variants was determined in silico using 
the ESEfinder 2.0, Human Splicing Finder 
(HSF), Sorting of Intolerant From Tolerant 
(SIFT), Transcription Element Search System 
(TESS). It must be emphasised that the results 
of such analyses are indicators of probable 
effects rather than definitive proof thereof. 
The final effect of a given mutation may 
be influenced by a combination of factors 
not necessarily taken into account during a 
computational search for a specific effect.
Results
MLPA analysis
The MLPA revealed eight exonic changes 
(five deletions and three duplications) 
previously undetected with the mPCR assay 
(Table 1), which was not capable of detecting 
duplications or deletions located outside of its 
range, largely limited to the deletion hotspots. 
The superior informativity of the MLPA in 
comparison with the previously used mPCR 
was clearly demonstrated here (as also shown 
by colleagues in Johannesburg).[7] The MLPA 
findings were confirmed by repeat MLPA 
and single-exon PCRs. No further analyses 
were carried out to confirm pathogenicity, as 
exonic rearrangements are an accepted cause 
of D/BMD.T
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Interestingly, the predicted effects of both duplication mutations 
detected were in conflict with the recorded phenotype. This is in fact 
consistent with the literature, where authors warn that while reading-
frame predictions are useful, DNA-based predictions of duplications 
in particular should be viewed with caution, as the true nature of 
the rearrangements may not be known owing to events such as non-
tandem rearrangements or altered splicing.[10]
HrMCA and sequencing
At least one hrMCA variant profile was noted in each of the 16 
patients screened and variant profiles were noted in 218 (14%) of 
all the analysed PCR fragments (96 per patient). Cycle sequencing 
revealed sequence alterations in 54 (3%) of these hrMCA variants. 
This high number of false variants was attributed to the variable 
quality of the available DNA, as fresh blood specimens could not be 
obtained in every case. Also, the criteria applied for variant selection 
erred on the side of caution, to avoid missing disease-associated 
mutations.
Ten of the sequence alterations found were classified as disease-
causing (Table 2) and comprised seven truncating mutations (three 
nonsense and four frameshifts), one splice-site, one missense and 
one point substitution in the Dp427 promoter/exon1 region of the 
DMD gene. Of these, only two (c.4729C>T and c.6905G>A) (Fig. 3) 
had previously been recorded in the Leiden Open Variation Database 
(LOVD), Leiden muscular dystrophy pages (http://www.dmd.nl).[4] 
The remaining eight mutations were accepted as novel, based on the 
LOVD and a literature search. Truncating mutations (nonsense and 
frameshifts) in the DMD gene are generally accepted as pathogenic, 
as are mutations affecting splicing (Table 2). Bioinformatics tools 
(previously listed) were used to confirm this, and to determine the 
probable pathogenicity of the novel missense mutation in exon 7 
and the 5ʹUTR sequence change (Table 2). Testing of population 
cohorts of affected and wild-type samples yielded negative results, 
providing further evidence towards the pathogenic and private (i.e. 
patient/family specific) nature of both these mutations. It must 
again be mentioned that while the disease association suggested 
by such analyses is likely, a definitive elucidation of their role in 
disease pathogenesis can only be achieved with mRNA expression 
and functional studies, all of which were beyond the scope of this 
project.
Where possible, archived DNA from family members was tested 
with PCR, restriction endonuclease (RE) or sequence analysis for the 
putative change identified in the proband. In each case, the mutation 
was shown to segregate with the affected phenotype. This did not 
provide definitive proof as the variant could simply segregate with 
the inherited chromosome, but went towards strengthening the case 
for pathogenicity.
Also identified were 41 benign polymorphisms, two of which 
were novel (data not shown). The assumption of non-pathogenicity 
was based their presence in multiple patients, co-segregation with 
pathogenic mutations, and/or previous reports of non-pathogenicity 
in the LOVD. Study findings also revealed three sequence alterations 
of uncertain clinical significance (data not shown), viewed as probably 
benign owing to their location at the 3ʹUTR and close proximity to 
other changes listed as non-pathogenic in the DMD LOVD. However, 
since no other pathogenic changes were found in these patients, 
additional studies are required to definitively exclude or establish 
their significance.
No disease-associated mutations were identified in eight 
patients in the cohort. The reasons for this may be threefold. 
Firstly, the clinical diagnosis was not confirmed with muscle 
biopsies in four of these cases and in the absence of genetic 
diagnoses, clinical reassessments may be warranted. Secondly, in 
some cases only archived DNA extracted using different methods 
was available, which may have resulted in missed variants owing to 
compromised DNA integrity or the presence of impurities known 
to influence the outcomes of hrMCA. Lastly, some of the patients 
could carry deep intronic mutations resulting in novel splice 
sites and inclusion of intronic sequences into the mRNA. These 
‘pseudoexon mutations’ cannot be picked up with DNA-based 
testing and the methods used here, owing to the exceptionally 
large size of the DMD introns, and require analysis of mRNA from 
muscle tissue.[17]
Discussion
In recent years, much effort has gone into investigating method-
ologies for comprehensive mutation detection in D/BMD, driven 
by the prospects of availability of mutation-based therapies. With 
that in mind, the major aim of this study was testing hrMCA as 
a screening tool for detection and characterisation of small/point 
mutations in the DMD gene in the local laboratory environment. We 
view identification of pathogenic mutations in ten out of 16 patients 
tested as a positive outcome, which has provided a significant part 
of the cohort and their families with previously unavailable genetic 
diagnoses.
The method employed (hrMCA) was chosen for its ease 
and cost-effectiveness as a mutation scanning tool. In contrast 
to the diagnostic laboratories in developed countries, where 
Table 2. Disease-associated small mutations detected
No. Variant Translational effect Times detected/ ethnicity Dystrophin domain New?*
1 c.620T>G (exon 7) Nonsense p.(Leu207X) × 1/coloured Actin-binding domain Yes
2 c.4729C>T (exon 34) Nonsense p.(Arg1577X) × 1/coloured Central rod domain repeat 12 No*
3 c.6905G>A (exon 47) Nonsense p.(Trp2302X) × 1/white Central rod domain repeat 18 No*
4 c.503delC (exon 6) Frameshift p.(Ala168fsX2) × 1/coloured Actin-binding domain Yes
5 c.836_837delCG (exon 9) Frameshift p.(Thr278fsX8) × 1/black Central rod domain repeat 1 Yes
6 c.8284dupA (exon 56) Frameshift p.(Iso2762fsX10) × 1/coloured Central rod domain repeat 22 Yes
7 c.8028_8031dupGGTG (exon 55) Splice/frameshift p.Val2677fsX4 × 1/black Central rod domain repeat 22 Yes
8 c.2293-1G>A (exon 19) Splice × 1/coloured Central rod domain repeat 4 Yes
9 c.-85T>C (Dp427m/exon1) 5ʹUTR × 1/coloured Transcription factor binding site Yes
10 c.587T>C (exon 7) Missense p.(Leu196Pro) × 1/unknown Actin-binding domain Yes
*As per literature search and the Leiden Open Variation Database (LOVD), Leiden muscular dystrophy pages (http://www.dmd.nl).[4]
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DNA sequencing is relatively inexpensive, the local cost of 
direct sequencing is high, at approximately ZAR100.00 per PCR 
fragment at the time of the study. This is a conservative estimate, 
which only partially factors in the cost of consumables and the 
analyst’s time. The size of the DMD gene, where approximately 96 
PCR fragments must be sequenced to cover its coding region (with 
genomic DNA as a template), makes direct sequencing in the local 
context prohibitively expensive. This cost is considerably reduced 
with the use of a presequencing mutation scanning tool such as 
the hrMCA, at ~R7.00 per PCR fragment. Once a putative ‘family’ 
mutation is identified in the proband, testing of other members of 
the family can be performed cheaply by targeting a specific region 
of the gene with PCR, RE or sequencing analysis.
Research involving point mutation detection in the DMD gene 
has previously been conducted locally. However, this is the first 
study in SA, and to our knowledge on the African continent, to 
take an all-encompassing approach to mutation profiling across 
the coding region of the DMD gene, i.e. detection of exonic 
rearrangements with the MLPA and small/point mutation detection 
with hrMCA and sequencing. Future plans for the molecular genetic 
service for DMD include establishing massive parallel sequencing 
as a diagnostic platform, which will further improve local mutation 
detection capabilities. An additional consideration is the superior 
nature of RNA-based analysis for definitive determination of 
the downstream effects of sequence alterations.[16] However, this 
requires muscle tissue sampling, which is invasive and is typically 
undertaken only in cases of clinically suspected D/BMD with 
negative results of molecular studies. This may change in the 
future, should RNA analysis become essential for ascertainment of 
eligibility for a mutation-based therapy. Until such time, however, 
DNA extracted from blood lymphocytes is likely to remain the 
mainstay of diagnostic testing.
Conclusion
The work described here provides the foundation for establishing 
a cost-effective, comprehensive and specific testing strategy 
for every D/BMD family. Furthermore, defining the mutations 
underlying the D/BMD phenotype in the SA population will 
facilitate establishing trends within the various population 
subgroups of SA, possibly correlating molecular features to the 
disease course and facilitating a more strategised approach to the 
clinical and laboratory diagnostic protocols. The knowledge of 
the disease-causing mutations detected during this study provides 
patients and their families with a considerable head-start in the 
future, when mutation-based genetic therapy becomes a veritable 
therapeutic avenue.
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